MediWound (NASDAQ:MDWD) Announces Quarterly Earnings Results, Beats Expectations By $0.42 EPS

MediWound (NASDAQ:MDWD) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.42, RTT News reports. MediWound had a negative return on equity of 65.79% and a negative net margin of 140.80%.The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $3.37 million. During the same quarter in the prior year, the company posted ($0.07) EPS.

Here are the key takeaways from MediWound’s conference call:

• EscharEx remains the company’s main development priority, but the VALUE Phase III study has been pushed back by one quarter, with enrollment now expected to finish by the end of Q1 2027. Management said the delay was driven by operational issues in Europe and the burden of frequent wound assessments, not by safety or efficacy concerns.
• The company said its EscharEx collaboration network has expanded to include nearly all major advanced wound care players, now adding Medline. This broader industry involvement was presented as external validation of EscharEx and could support future commercialization and additional studies in DFU and pressure ulcers.
• NexoBrid continued to gain commercial and strategic traction, with Vericel reporting growth in ordering centers and total orders in the U.S. burn market. MediWound also highlighted a new 10-year BARDA contract worth up to $197 million, with procurement and development expected to begin in the second half of 2026.
• First-quarter 2026 revenue fell to $1.5 million from $4.0 million a year earlier, mainly because of the timing of BARDA-related revenue and shipment delays tied to regional conflict. The quarter also reflected higher R&D spending on the EscharEx VALUE study, contributing to a wider operating loss.
• Management reaffirmed full-year 2026 revenue guidance of $24 million to $26 million, expecting a second-half weighted ramp from government-related development services and procurement. The company said it is working through EMA pre-audit modifications at its expanded manufacturing facility and expects those activities to be completed in the second half of 2026.

MediWound Trading Down 6.0%

MDWD opened at $15.67 on Wednesday. MediWound has a 12 month low of $14.90 and a 12 month high of $22.50. The stock has a fifty day moving average price of $16.79 and a 200-day moving average price of $17.51. The firm has a market cap of $201.39 million, a price-to-earnings ratio of -7.56 and a beta of 0.21.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. lifted its stake in shares of MediWound by 24.3% in the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after purchasing an additional 45,077 shares during the period. Kotler Kevin acquired a new stake in MediWound in the 4th quarter worth about $6,225,000. Russell Investments Group Ltd. increased its stake in MediWound by 45.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 1,135 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of MediWound during the fourth quarter valued at approximately $297,000. Finally, Barclays PLC raised its holdings in shares of MediWound by 32.5% during the fourth quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 3,747 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MDWD. Wall Street Zen lowered MediWound from a “hold” rating to a “strong sell” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research note on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $35.00.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.